Hiroto Hatano

Dr. Hiroto Hatano

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2024 in Thoracic Cancer
Verified
Journal Article
Open access
HHHiroto Hatano
Hiroto Hatano
TYTatsuya Yoshida
Tatsuya Yoshida
RHRyoko Higashiyama
Ryoko Higashiyama
MTMasahiro Torasawa
Masahiro Torasawa
YUYuji Uehara
Yuji Uehara
YOYuichiro Ohe
Yuichiro Ohe
Concurrent mutations in tumor protein p53 (TP53) or Kelch‐like ECH‐associated protein 1‐nuclear factor erythroid 2‐related factor 2‐pathway components are linked to poor outcomes in epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC), but the impact of triple mutations remains unclear. We report a case of EGFR‐, TP53‐, and Cullin 3 (CUL3)‐mutant NSCLC in a 43‐year‐old woman with widespread metastases at diagnosis, including those in the contralateral lung, distant lymph nodes, pericardium, liver, bones, left adrenal gland, and brain. She received osimertinib as first‐line therapy, but pericardial effusion and liver metastases progressed rapidly over 3 months, and she was switched to carboplatin and pemetrexed. By the eighth cycle of pemetrexed, the bone metastases had progressed, resulting in disseminated intravascular coagulation (DIC) due to bone marrow carcinomatosis. The patient received third‐line therapy with albumin‐bound paclitaxel and fourth‐line therapy with docetaxel, but further treatment was suspended owing to DIC progression. She passed away 23 months after the initiation of osimertinib. Public database analysis revealed that the EGFR/TP53/CUL3 triple mutation accounts for 0.4% of EGFR‐mutant NSCLC cases, yielding significantly shorter survival than EGFR mutations alone and likely shorter than EGFR/TP53 double mutations. Gaining a deeper understanding of the clinical significance of coexisting genetic mutations in patients with EGFR‐mutant NSCLC will be crucial to develop future therapies.

9 November 2024 in Respiratory Investigation
Verified
Journal Article
Closed access
HHHiroto Hatano
Hiroto Hatano
MSManabu Suzuki
Manabu Suzuki
MSMio Sugino
Mio Sugino
MNMikako Nakamura
Mikako Nakamura
YKYusaku Kusaba
Yusaku Kusaba
MHMasayuki Hojo
Masayuki Hojo

25 June 2026 in Lung Cancer
Verified
Journal Article
Closed access
HHHiroto Hatano
Hiroto Hatano
YUYuji Uehara
Yuji Uehara

8 April 2025 in Chest
Verified
Journal Article
Closed access
HHHiroto Hatano
Hiroto Hatano
TATaisuke Akamatsu
Taisuke Akamatsu
TSToshihiro Shirai
Toshihiro Shirai

31 August 2026 in Lung Cancer
Verified
Journal Article
Closed access
HHHiroto Hatano
Hiroto Hatano
TYTatsuya Yoshida
Tatsuya Yoshida
RHRyoko Inaba Higashiyama
Ryoko Inaba Higashiyama
MSMasayuki Shirasawa
Masayuki Shirasawa
YNYoshiro Nakahara
Yoshiro Nakahara
YGYasushi Goto
Yasushi Goto

25 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
YUYuji Uehara
Yuji Uehara
HHHiroto Hatano
Hiroto Hatano
JZJia-Tao Zhang
Jia-Tao Zhang
Jiefei HanJiefei Han
Jiefei Han
KCKevin L. M. Chua
Kevin L. M. Chua
SSStephanie Pei Li Saw
Stephanie Pei Li Saw
The discovery of activating epidermal growth factor receptor (EGFR) mutations transformed the management of non-small cell lung cancer and has driven two decades of therapeutic advances in precision oncology across metastatic, resectable, and unresectable locally advanced disease, including central nervous system (CNS) control. Consequently, treatment outcomes for patients with tumors harboring classical EGFR mutations have markedly improved. Despite these advances, many questions remain unanswered, and the expanding number of treatment options has created new challenges in treatment selection and sequencing. This narrative review summarizes contemporary data on the management of classical EGFR-mutant NSCLC, encompassing novel therapeutic approaches across disease stages, biomarker-informed resistance strategies, multimodality treatment integrating radiotherapy, CNS-directed management, and challenging scenarios such as small-cell transformation. We also discuss emerging fourth-generation inhibitors, nucleic-acid delivery platforms, and data-enabled personalized treatment. We highlight evolving standards of care, unresolved knowledge gaps, and research priorities for the next decade.